GLSI: net income -$19.4M. GLSI reports worsening internal controls, 36% cash burn rise as Phase III trial scales

Filed June 1, 2026 · Period ending December 31, 2025 · Compared to 10-K Apr 15, 2025 · ~2 min read

Key Changes

• high

  Material weaknesses in internal controls expanded from two deficiencies to four, adding lack of accounting systems for financial reporting/stock awards and insufficient expense report controls. Management now identifies weaknesses across all prior periods, not just Q3 2020.

  Controls & Risk Factors verify on EDGAR →
• high

  Operating cash burn jumped 36% to $9.9M (from $7.3M prior year) as Phase III Flamingo-01 trial expanded, outpacing the 11% increase in reported R&D expense and suggesting accelerated trial-related payments.

  MD&A: Cash Flow verify on EDGAR →
• high

  Net loss rose 12% to $19.4M (vs. $17.4M restated prior year), driven by Phase III trial costs. Accumulated deficit deepened to $87.1M from $66.2M, reflecting sustained pre-revenue burn.

  MD&A & Risk Factors verify on EDGAR →